Coronary Artery Calcium Scoring
A Powerful Tool for Personalizing Cardiovascular Prevention
What Is Coronary Artery Calcium Scoring?
Coronary artery calcium (CAC) scoring is a non-invasive imaging test that quantifies the amount of calcified plaque in the coronary arteries. The test uses a rapid, non-contrast electrocardiogram-gated CT scan that takes only seconds to perform and exposes patients to minimal radiation.
The calcium detected represents a marker of overall coronary atherosclerosis burden. While calcium is incorporated into most plaques as part of the body’s reparative process, it doesn’t directly indicate whether arteries are obstructed. Instead, it serves as a powerful predictor of future cardiovascular events.
The most widely used quantification method is the Agatston score, which multiplies the area of calcified atherosclerosis by a density weighting factor for each CT slice, then sums these values across the entire coronary arterial tree. Scores range from zero (no detectable calcium) to over 1,000 in severe cases.
What Do Medical Societies Recommend?
The 2019 ACC/AHA guidelines and the updated 2026 dyslipidemia guidelines recommend CAC scoring primarily for risk stratification in asymptomatic adults at intermediate risk (7.5-20% 10-year ASCVD risk) when decisions about preventive therapies remain uncertain. The test may also be considered for borderline-risk individuals (5-7.5% 10-year risk) with risk-enhancing factors.
Major international guidelines—including those from the Canadian Cardiovascular Society, the Cardiac Society of Australia and New Zealand, and European societies—show remarkable consensus on key principles:
When CAC scoring may be indicated:
- Adults over 40 years of age
- Asymptomatic individuals at intermediate risk
- Situations where treatment decisions remain unclear despite traditional risk assessment
- Presence of risk-enhancing factors (family history of premature ASCVD, chronic kidney disease, metabolic syndrome, inflammatory diseases, or conditions specific to women like preeclampsia)
When CAC scoring is NOT recommended (per these guidelines):
- Individuals already taking statins
- Those with known ASCVD
- Patients with diabetes, current smoking, or familial hyperlipidemia (statin therapy already recommended regardless of CAC score)
- Adults under 40 years (calcified plaque infrequently seen)
Note that the above recommendations are not necessarily what I would suggest as there are nuances to these decisions.
How CAC Scores Guide Treatment Intensity
The real power of CAC scoring lies in its ability to personalize cardiovascular prevention strategies. Here’s how different scores translate to treatment recommendations:
CAC = 0: A zero score identifies individuals at lower actual risk than predicted by traditional risk calculators. Guidelines universally agree this supports withholding or postponing statin therapy in most cases, particularly in lower-risk patients without additional risk factors like diabetes, heavy smoking, or strong family history of premature ASCVD. The 10-year event rate for those with CAC of zero is typically under 5%, and these individuals appear to derive little benefit from statins. For those over 40 with an initial CAC of zero, repeat testing may be considered after 5 years.
CAC 1-99: This range indicates the presence of subclinical atherosclerosis but represents a gray zone. The 2026 ACC/AHA guidelines recommend treatment with LDL-lowering therapies (statins as first-line) to achieve at least a 30% reduction in LDL-C and a goal of 100 mg/dL, particularly for scores below the 75th percentile for age, sex, and race. Statin therapy is especially favored for individuals over 55 years or those under 45 years (where any detectable calcium is more concerning).
CAC ≥100: This threshold clearly indicates statin therapy is warranted. The presence of this much calcium reclassifies patients to higher risk categories where statin benefit is well-established.
CAC ≥300: Individuals with scores this high have cardiovascular event rates comparable to those with established ASCVD. The 2026 guidelines suggest it may be reasonable to pursue more aggressive LDL-C lowering to 55 mg/dL—the same goal recommended for secondary prevention.
Individualizing Medical Management Based on CAC
Beyond simple threshold-based decisions, CAC scoring enables truly personalized risk discussions. Consider these scenarios:
The uncertain intermediate-risk patient: A 58-year-old woman with borderline high cholesterol and a calculated 10-year ASCVD risk of 12% is uncertain about starting a statin. A CAC score of zero could provide reassurance that her actual risk is lower than calculated, allowing her to defer medication while focusing on lifestyle interventions. Conversely, a score of 150 would provide concrete evidence of subclinical disease, often motivating both physician and patient toward more aggressive management.
The young patient with risk factors: A 42-year-old man with metabolic syndrome and a family history of early heart disease has a relatively low calculated 10-year risk due to his age. However, a CAC score of 75 reveals he already has significant atherosclerosis, reclassifying him to higher risk and justifying earlier intervention.
Motivating lifestyle change: The visual evidence of coronary calcium can be a powerful motivator for patients to adhere to lifestyle modifications and medications. Seeing objective evidence of disease often resonates more than abstract risk percentages.
Guiding intensity of risk factor management: Beyond just statin decisions, CAC scores can inform how aggressively to manage blood pressure, how strictly to control diabetes, and whether to consider additional therapies like PCSK9 inhibitors in appropriate candidates.
Important Limitations: The Risk of False Negatives
While CAC scoring is a powerful tool, it has important limitations that clinicians and patients must understand. The most significant is that a zero CAC score does not completely rule out coronary artery disease.
CAC scoring only detects calcified plaque. Early-stage atherosclerosis presents as non-calcified (soft) plaque, which is invisible on calcium scoring. Studies show that approximately 14% of patients with flow-limiting stenoses may have a CAC score of zero. While the overall prevalence of obstructive CAD in patients with CAC of zero is relatively low (around 2-6% in most studies), this varies significantly by patient population.
Who is at highest risk for false negatives?
Younger patients:This is the most important group to recognize. In patients under 45 years, the sensitivity of CAC scoring drops substantially. One large study found that among patients 40-49 years old with obstructive CAD, one in three had a CAC score of zero. The sensitivity of CAC = 0 for ruling out obstructive CAD in patients under 45 was only 82%, compared to over 95% in older populations. This occurs because younger patients with atherosclerosis are more likely to have predominantly non-calcified plaque that hasn’t yet undergone calcification.
Women: Women with obstructive CAD more frequently have non-calcified plaque compared to men. This sex difference means that CAC scoring may be less sensitive in women, particularly younger women.
Patients with acute presentations: While CAC scoring is primarily used in asymptomatic individuals, it’s worth noting that acute coronary syndromes can occur from rupture of non-calcified plaques. This is why CAC scoring is not recommended for symptomatic patients with suspected acute coronary syndrome.
Patients with specific risk factors: Even with CAC of zero, clinicians should not downgrade risk in patients who are persistent cigarette smokers, have diabetes, have a strong family history of ASCVD, or have chronic inflammatory conditions. In these populations, a zero CAC score doesn’t rule out risk from non-calcified plaque or increased thrombotic risk.
The bottom line: CAC scoring is an excellent tool for risk stratification in the appropriate population—primarily asymptomatic adults over 40-45 years at intermediate risk. It provides objective evidence of subclinical atherosclerosis that can guide personalized decisions about the intensity of preventive therapies. However, it should be used as part of comprehensive risk assessment, not in isolation, and clinicians must recognize its limitations, particularly in younger patients and women where false negatives are more common.
Dr. Schraga is a concierge physician at CrescendoMD in the San Francisco Bay Area who focuses on prevention, longevity, and personalized primary care. He writes here about how emerging science and innovation are shaping the future of health.
